HEALTH & LIFE SCIENCES NEWS
HEALTH & LIFE SCIENCES NEWS
Exploring Critical Business and Legal Issues across the Healthcare and Life Sciences Industries
HEALTH & LIFE SCIENCES NEWS
Exploring Critical Business and Legal Issues across the Healthcare and Life Sciences Industries

Avatar McDermott Will & Emery

Subscribe to McDermott Will & Emery's Posts

McDermott Will & Emery and EY during the 2021 J.P. Morgan Healthcare Conference: Hospital and Health Systems: Legal and Financial Trends


By on Feb 10, 2021
Posted In Digital Health, Hospitals & Health Systems, Life Sciences

Leading professionals Gary Burke (Partner, Forensics, EY), Sandy DiVarco, and Jennifer Geetter (Partners, McDermott Will & Emery), Mike J. India (Managing Director, EY-Parthenon) and Matthew Weiss, MD (EY-Parthenon Managing Director, Health care, Ernst & Young LLP) discussed critical legal, regulatory and financial trends facing hospitals and health systems with moderator, Charlie Buck (Partner, McDermott Will...

Continue Reading



McDermott Will & Emery and EY during the 2021 J.P. Morgan Healthcare Conference: Hospital and Health System CEO Panel: Strategic Business Priorities


By on Jan 29, 2021
Posted In Hospitals & Health Systems, Life Sciences

Our panel included a discussion on what is ahead for 2021 and how the challenges of COVID-19 will lead to lasting changes for hospitals and health systems, with Lloyd Dean (CEO, CommonSpirit), Melinda Estes, MD (President and CEO, St. Luke’s Health System) and Jaewon Ryu, MD (President and CEO, Geisinger). These top healthcare leaders discussed...

Continue Reading



McDermott Will & Emery and EY during the 2021 J.P. Morgan Healthcare Conference: Digital Health Pioneers Forum


By on Jan 28, 2021
Posted In Digital Health, Life Sciences

    Top industry executives BJ Moore, Executive Vice President and Chief Information Officer, Providence St. Joseph Health; Dr. Ali Parsa, Chief Executive Officer, Babylon Health; and Lucia Savage, Chief Privacy and Regulatory Officer, Omada Health, discussed the evolving doctor-patient relationship and the digitized data and technology convergence with healthcare delivery and payment along with...

Continue Reading



McDermott Will & Emery and EY during the 2021 J.P. Morgan Healthcare Conference: Election and Policy Implications: Healthcare Regulatory and Policy Outlook with the New Administration


By on Jan 28, 2021
Posted In Life Sciences Private Equity, Uncategorized

The 2020 election gave Democrats the White House and control of both houses of Congress-an eleven seat majority in the House and Representatives, and a 50/50 split in the Senate with Vice President-elect Kamala Harris available to break ties. This change in the political landscape will lead to shifts in the health policy and regulatory...

Continue Reading



Life Sciences Dealmaking Symposium: As the Dust Settles: Post-Election Update and Impact on the Life Sciences Industry


By on Dec 11, 2020
Posted In Digital Health, Life Sciences

How will the election affect life sciences in 2021 and beyond? What’s ahead for the regulatory and policy environment? In this session, our elite group of policy analysts reviewed the election results and the far-reaching effects for dealmakers, executives and investors. Eric Zimmerman, global head of McDermott’s Health Industry Advisory Practice Group, moderated this discussion...

Continue Reading



Life Sciences Dealmaking Symposium: Powering through the Pandemic: Trends in Early-Stage Investment


By on Dec 11, 2020
Posted In Digital Health, Life Sciences

The pursuit of progress during these unprecedented times has led to a surge in life sciences investment and funding for early stage companies. Investors are on the lookout for the next big innovation while also navigating new ways of sourcing and managing portfolio companies. Our panel of experienced early-stage investors discussed the top trends in...

Continue Reading



Life Sciences Dealmaking Symposium: New Factors in the Mix: Diligence in the Time of COVID-19


By on Dec 11, 2020
Posted In Digital Health, Life Sciences

Navigating the ever-changing global life sciences deal landscape has become more challenging in the post-pandemic world. Conducting virtual inspections and examining security and privacy risks for remote working and new operating procedures will be central to evaluating current and future collaboration partners and targets. Thinking quickly yet carefully is essential for successfully adapting to this...

Continue Reading



Hospital and Health System Innovation Summit: Lessons Learned: Diligence, Detours and Data, Oh My


By on Nov 20, 2020
Posted In Health M&A, Hospitals & Health Systems

Industry leaders shared first-hand lessons learned from their work on recent innovation related projects. We covered a range of case studies, highlighting lessons learned around mission alignment, conflicts of interest, diligence considerations, data ownership and de-identification, and strategies for protecting a minority investor. Below are the top takeaways for Hospital and Health System Innovation Summit:...

Continue Reading



Hospital and Health System Innovation Summit: Pandemic to Partnership: The Impact of Covid-19 on Innovation


By on Nov 20, 2020
Posted In Uncategorized

In this interactive discussion, health system innovation leaders addressed the impact of COVID-19 on health systems’ plans to pursue innovation efforts; the lasting implications of the pandemic; and the prioritization of innovation efforts and investments post-COVID-19. McDermott Will and Emery’s Partner Kerrin B. Slattery moderated this discussion featuring insights from Lisa Prasad, Vice President and...

Continue Reading



Hospital and Health System Innovation Summit: Nuts And Bolts: How to Invest in Innovation


By on Nov 20, 2020
Posted In Health M&A, Hospitals & Health Systems

There has been increased interest by hospitals and health systems in creating innovation centers and making innovation center investments, which are helping to transform the healthcare landscape. As they enter this space, hospitals and health systems must first decide how to organize to capitalize on and commercialize innovation opportunities to get innovations into the routine...

Continue Reading



STAY CONNECTED

TOPICS

ARCHIVES